These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 25681662

  • 21. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
    Strezova A, Godeaux O, Aggarwal N, Leroux-Roels G, Lopez-Fauqued M, Van Damme P, Vanden Abeele C, Vastiau I, Heineman TC, Lal H.
    Vaccine; 2017 Dec 04; 35(48 Pt B):6700-6706. PubMed ID: 29079101
    [Abstract] [Full Text] [Related]

  • 22. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, Zhao Y, Parrino J, Popmihajlov Z.
    Clin Infect Dis; 2017 Oct 01; 65(7):1174-1182. PubMed ID: 29126292
    [Abstract] [Full Text] [Related]

  • 23. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, Canniff J, Johnson MJ, Caldas Y, Cho A, Lang N, Su SC, Parrino J, Popmihajlov Z, Weinberg A.
    J Infect Dis; 2016 Jan 01; 213(1):14-22. PubMed ID: 26452397
    [Abstract] [Full Text] [Related]

  • 24. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
    Chun JY, Kim K, Lee MK, Kang CK, Koh Y, Shin DY, Hong J, Choe PG, Kim NJ, Yoon SS, Park WB, Kim I, Oh MD.
    BMC Infect Dis; 2021 Jan 26; 21(1):117. PubMed ID: 33499826
    [Abstract] [Full Text] [Related]

  • 25. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.
    Sutradhar SC, Wang WW, Schlienger K, Stek JE, Xu J, Chan IS, Silber JL.
    Clin Vaccine Immunol; 2009 May 26; 16(5):646-52. PubMed ID: 19261769
    [Abstract] [Full Text] [Related]

  • 26. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
    Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, Biswas P, Needle E, Passador S, Mojcik CF, Rigby WF.
    Arthritis Rheumatol; 2017 Oct 26; 69(10):1969-1977. PubMed ID: 28845577
    [Abstract] [Full Text] [Related]

  • 27. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
    MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, Pagnoni MF, Stek JE, Xu J, Annunziato PW, Chan IS, Silber JL.
    Hum Vaccin; 2010 Nov 26; 6(11):894-902. PubMed ID: 20980796
    [Abstract] [Full Text] [Related]

  • 28. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.
    Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, Rombo L, Sonder G, Smetana J, Heineman T, Bastidas A.
    Hum Vaccin Immunother; 2018 Jun 03; 14(6):1370-1377. PubMed ID: 29461919
    [Abstract] [Full Text] [Related]

  • 29. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.
    Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J.
    J Infect Dis; 2013 Nov 01; 208(9):1386-90. PubMed ID: 23908486
    [Abstract] [Full Text] [Related]

  • 30. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.
    Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, Pergam SA, Mullane MR, Stek JE, Sterling TM, Zhao Y, Manoff SB, Annunziato PW.
    J Infect Dis; 2013 Nov 01; 208(9):1375-85. PubMed ID: 23908479
    [Abstract] [Full Text] [Related]

  • 31. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve.
    Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, Parrino J, Chan IS.
    J Infect Dis; 2014 Nov 15; 210(10):1573-81. PubMed ID: 24823623
    [Abstract] [Full Text] [Related]

  • 32. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.
    Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, Halsey NA, Gershon AA.
    Vaccine; 2017 Dec 19; 35(52):7231-7239. PubMed ID: 29174682
    [Abstract] [Full Text] [Related]

  • 33. The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.
    Weinberg A, Pang L, Johnson MJ, Caldas Y, Cho A, Tovar-Salazar A, Canniff J, Schmader KE, Popmihajlov Z, Levin MJ.
    J Virol; 2019 Aug 01; 93(15):. PubMed ID: 31092579
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
    Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, Schwarz TF, Catteau G, Lal H, Heineman TC.
    Vaccine; 2016 Feb 03; 34(6):863-8. PubMed ID: 26432913
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER, Lewis P, Shimabukuro TT, Su J, Moro P, Woo EJ, Jankosky C, Cano M.
    Hum Vaccin Immunother; 2018 Feb 03; 14(8):1963-1969. PubMed ID: 29580194
    [Abstract] [Full Text] [Related]

  • 39. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
    Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC.
    J Infect Dis; 2013 Dec 15; 208(12):1953-61. PubMed ID: 23904292
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.